Treace Medical Concepts, Inc. · NASDAQ:TMCI
Treace Medical Concepts — Q1 2024 Earnings Presentation
14 slides from Treace Medical Concepts's earnings presentation, May 7, 2024
Slide 1: First Quarter 2024 Earnings Presentation
First Quarter 2024 Earnings Presentation May 7, 2024 On solid footing for sustained top-tier growth 1
Slide 2: Forward-Looking Statements
This presentation may include forward- looking statements. All statements other than statements of historical facts contained in this presentation, including, but not limited to, statements regarding our updated full year 2024 guidance, including our anticipated improvement in Adjusted EBITDA, antic
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures 3 To supplement the financial results presented in accordance with GAAP, this presentation presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expe
Slide 4: Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc. Pure-play medical device company focused on the surgical treatment of bunions and related deformities 63 US PATENTS1 20 WORLDWIDE PATENTS 83 US PENDING PATENTS Growing FY 2023 revenue of $187.1 million (+32% YOY growth) 5-year revenue growth CAGR of +60% Just getting st
Slide 5: 1Q 2024 Results Summary
1Q 2024 Results Summary $ in millions, except % 1Q’24 Y-Y Change Revenue $51.1 +21% Gross Margin 80.2% -70 bps Net Loss $(18.7) -39% Non-GAAP Adjusted EBITDA¹ $(8.3) +18% Delivered gains across key operating metrics in Q1 2024: Drove a year-over-year increase in volume of Lapiplasty®, Adductoplasty®
Slide 6: 1Q 2024 Key Messages
1Q 2024 Key Messages 6 Revenue YoY growth of +21% represents strong start to 2024 Net loss attributable to common stockholders was ($18.7) million in first quarter 2024 compared to ($13.5) million for same period in 2023. Adjusted EBITDA loss improved 18% to ($8.3) million in first quarter 2024 comp
Slide 7: SpeedPlate Fixation Platform
“The biggest thing from Treace since Lapiplasty®” “Total game changer” Fixation Platform, a giant step forward SpeedPlate™ - a new standard for foot and ankle fixation for Lapiplasty®, Adductoplasty® and BEYOND. We expect it to fuel revenue growth and new surgeon additions. SURGEONS SAY: 7 SpeedPlat
Slide 8: Building on our strengths: Powerful Future Pipeline
Building on our strengths 8 Powerful Future Pipeline REDPOINT™ PSI TECHNOLOGY Pre-operative planning and patient-specific cut guides Strengthens market leadership position and competitive differentiation First to U.S. market with FDA-cleared PSI solution for bunion and midfoot deformity correction N
Slide 9: Mini-Adductoplasty System
Coming in 2H 2024 Mini-Adductoplasty™ System 9 MTA: Metatarsus adductus (1) American College of Foot and Ankle Surgeons Website (2) Nix S, et al. J Foot Ankle Res 2010; Sep 27:3:21 (3) Aiyer AA, et al. FAI 2016; 37:165-171 (4) Aiyer AA, et al. FAI 2014; 35:1292-1297 Designed to be performed through
Slide 10: Expanding Patient Education and Awareness
Expanding Patient Education and Awareness New Future You campaign premiered on season finale of The Bachelor First-Ever National Bunion Day on April 16 Official Foot and Ankle Solution Partner Professional Pickleball Association Tour TMC Data on file
Slide 11: Updated Full-Year 2024 Guidance
Updated Full-Year 2024 Guidance 11 Guidance range communicated on 5/7/2024. The fact that we include these projections in this presentation should not be taken to mean that these amounts continue to be our projections as of any subsequent date. See slide 2 entitled “Forward-Looking Statements” for m
Slide 12: Solid footing, setting the pace
Solid footing, setting the pace Differentiated technology and innovative procedures backed by compelling clinical evidence Positioned to deliver steady cadence of new innovations in the second half of 2024 Expect to make significant improvement in Adjusted EBITDA for FY 2024 Pioneer in foot and ankl
Slide 13: For Additional Information, Please Contact
FOR ADDITIONAL INFORMATION, PLEASE CONTACT: www.treace.com NASDAQ: TMCI Julie Dewey, IRC jddewey@treace.com 209-613-6945 13 Chief Communications & Investor Relations Officer
Slide 14: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations 14
Treace Medical Concepts — Q1 2024 Earnings Presentation on 6ix